Mesa Laboratories, Inc.
MLAB
NASDAQ·Healthcare·Medical - Specialties·Mkt cap $715.0M
$127.78
▼ -0.58%
P/E
52.16
Mkt Cap
$715.0M
52-Wk Range
$58.83–$132.70
52-Week Range
$58.83 - $132.70
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 100.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized expertise and regulatory certifications in mission-critical quality control applications that are difficult to replicate
- Recurring revenue model through consumables (indicators, reagents, kits) that lock in customer relationships
- Diversified end-markets reduce dependency on single industry; presence across pharma, medical devices, hospitals, and clinical labs
- Established distribution networks and customer relationships built over 40+ years of operation
- High barriers to entry due to regulatory requirements, validation processes, and technical complexity
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Steady revenue growth (11% YoY)
Value
Attractively priced below Electronics Manufacturing Services peer average
Momentum
Strong
+17.8% over 3m
Quality
Excellent
Excellent business quality
Dividend
Modest
0.50% yield
Smart-money signal
Who's buying MLAB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 10, 2026
Reported EPS of $2.68 vs $2.63 consensus (+1.9% surprise). Revenue of $60.1M vs $60.9M expected (-1.2%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+1.9%
Revenue trend · last 8Q
—
—
+18%
+5%
+2%
+5%
+4%
+1%
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q1 27
$58.2M
$57.8M
$62.8M
$62.1M
$59.5M
$60.7M
$65.1M
$60.1M
Margins · last 8Q
Gross
64.9%
Operating
11.7%
Profit
4.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How MLAB stacks vs Medical - Specialties
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related